The endogenous TLR-4 ligands MRP8/14 as biomarkers of inflammation in Familial Mediterranean Fever (FMF) by Wittkowski, H et al.
BioMed  Central
Page 1 of 1
(page number not for citation purposes)
Pediatric Rheumatology
Open Access Poster presentation
The endogenous TLR-4 ligands MRP8/14 as biomarkers of 
inflammation in Familial Mediterranean Fever (FMF)
H Wittkowski*1, T Kallinich2, R Keitzer2, J Roth1 and D Foell1
Address: 1University Hospital Muenster, Department of Pediatrics, Muenster, Germany and 2Charite University Hospital Berlin, Department of 
Pediatrics, Berlin, Germany
* Corresponding author    
Background
The pro-inflammatory Damage Associated Molecular Pat-
tern (DAMP) molecules Myeloid-Related Protein (MRP)-
8/14 have been recently identified as ligands and activa-
tors of TLR-4. Familial Mediterranean Fever (FMF) is an
auto-inflammatory syndrome associated with activation
of phagocytic cells and oversecretion of the proinflamma-
tory cytokine IL-1β. Our aim was to evaluate MRP8/14
serum levels in FMF patients during high inflammatory
episodes and during successful therapy.
Patients and methods
70 genetically proven FMF patients were followed up lon-
gitudinally over a period of 18 months. Serum concentra-
tion of MRP-8/14 determined by ELISA and additionally
ESR, CRP and SAA as classical inflammation markers were
analysed before starting of therapy and during colchicine
treatment. As control groups we measured 17 Neonatal-
Onset Multisystem Inflammatory Disease (NOMID), and
18 Muckle Wells Syndrome (MWS) patients.
Results
The mean serum levels of MRP8/14 in inflammatory epi-
sodes in FMF (343,210 ± 202,210 ng/ml; n = 17) were sig-
nificantly higher than in NOMID (2,830 ± 580 ng/ml; p <
0.001), or in MWS (3,205 ± 585 ng/ml; p < 0.001). FMF
patients treated with colchicine and not exhibiting any
attacks during the study period (5,480 ± 1,900 ng/ml; n =
28) had significantly lower MRP8/14 levels than patients
treated with colchicine exhibiting complains typical for
FMF (34,700 ± 14,580 ng/ml; p < 0.001; n = 20), and also
than Homozygous patients never experiencing any clini-
cal signs without colchicine treatment (22,310 ± 10,110
ng/ml; p < 0.05 n = 5).
Conclusion
MRP8/14 as a marker of phagocyte activation is highly
oversecreted in patients with FMF. Measurement of
MRP8/14-levels in FMF might be a valuable tool to reflect
disease activity, response to anti-inflammatory therapy,
and even subclinical inflammatory activity.
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